.svg){kind=small}
For pharmaceutical companies, the integration of patient perspectives into HTA processes is not only beneficial - it is essential. This is especially true as the industry prepares for the upcoming implementation of Joint Clinical Assessments (JCA) in the European Union, which will standardize HTA assessments across member states.
Why is Patient Involvement in HTA Important?
Patient involvement in HTA brings a unique and invaluable perspective. Patients, by virtue of living with their conditions, are experts in understanding the real-world impact of diseases and treatments. They can provide insight into outcomes that matter most to them, such as quality of life, daily functioning, and treatment burden. Engaging with patients early in the development process ensures that pharmaceutical companies can design trials and treatments that not only meet regulatory requirements but also align with patient needs.
Historically, HTA bodies have relied heavily on clinical outcomes like morbidity and mortality. However, there is growing recognition that patient-reported outcomes (PROs), such as quality of life or ease of treatment adherence, should be given equal weight. Patient engagement ensures these dimensions are captured, making the resulting data more relevant to both payers and patients.
The Role of Patient Advocates in Joint Clinical Assessments
The European Union's push toward harmonizing HTA processes through JCAs represents a significant shift. By 2025, JCAs will streamline how new drugs and health technologies are evaluated across the EU, focusing on clinical evidence that demonstrates added value. Importantly, patients will have a more formalized role in these assessments.
Patient advocates are actively preparing to participate in JCAs, taking on roles as individual experts and contributors. Many organizations are collaborating to train patient representatives on HTA processes, ensuring they can provide meaningful input during assessments. This is a pivotal development, as patient involvement is expected to shape not just the evaluations but also the broader understanding of how treatments impact everyday life.
Moreover, pharmaceutical companies are recognizing the strategic importance of aligning with patient advocates early on. Patient-driven data is increasingly influencing regulatory and HTA outcomes. Companies that actively involve patients in shaping clinical trial designs and endpoint selections are more likely to succeed in achieving favorable HTA decisions.
How Pharmaceutical Companies Can Prepare
For those working in market access or medical affairs, patient involvement in JCAs is an opportunity to integrate patient preferences into submissions and enhance the overall relevance of clinical data. A few key steps can be taken to prepare:
- Incorporate Patient Insights Early: Start engaging patients during clinical trial design, not just at the regulatory submission phase. This ensures that trials are aligned with patient needs, making outcomes more compelling during HTA evaluations.
- Co-Create Evidence with Patients: Collaborating with patient groups to co-create Patient Reported Outcomes Measures (PROMs) and other relevant metrics adds credibility to the submission and demonstrates a commitment to patient-centered care.
- Train Internal Teams on HTA Processes: Companies should invest in training programs for internal teams and patient advocates to understand HTA methodologies and the nuances of JCA processes.
- Leverage Patient Advocacy: Build strong relationships with patient organizations. Their involvement not only improves the quality of data but also boosts credibility in discussions with HTA bodies.
Conclusion
As Europe prepares for the full implementation of Joint Clinical Assessments, patient involvement will be a critical factor in ensuring that new treatments are not only clinically effective but also relevant to patients’ lives. Pharmaceutical companies that proactively engage with patient advocates and incorporate patient perspectives into their HTA strategies will be better positioned to succeed in this new era of healthcare evaluation.
For those in market access, patient engagement, and medical affairs, the message is clear: Patients are not just subjects of healthcare but key stakeholders. Their voices must be integrated into every stage of the process—from trial design to HTA evaluation—to ensure treatments meet both regulatory standards and the real-world needs of those they serve.
If you want to discuss this topic in more detail, contact us!
